Antiosteoporosis Treatment May Decrease COVID-19 Incidence by 30-40%

A new joint study revealed that some of the treatments for osteoporosis could have a protective effect against COVID-19. The principal treatment for osteoporosis, zoledronate, denosumab, and calcium have a protective effect in patients who take them. These drugs could interfere with COVID-19 either decreasing its incidence or its progression. The study included 2000 patients with osteoporosis, fibromyalgia, and osteoarthritis. In case some main treatments for osteoporosis like calcium, zoledronate, and denosumab, data analysis revealed a major reduction in the incidence of COVID-19 in patients who take them; specifically, between 30 and 40%.

In the case of denosumab, it targets the RANK/RANKL system, which is involved in the balance of the skeletal system and the response by the immune system through the activation and differentiation of some of its cells. It modified the inflammatory response and acts on cytokines, which play a key role in infection by COVID-19. Zoledronate also modulates the immune response and can stimulate its activity against SARS-CoV-2. The results from this also indicated that duloxetine, which is another common treatment for these patients may also have a positive effect in reducing the incidence of COVID-19. Pregabalin tends to increase the incidence of the disease.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.aging-us.com/article/104117/text

#Featured